Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (6764)	4/9/1998 8:07:00 PM
From: av ram	Read Replies (1) \| Respond to of 23519

Following came in Dow Jones News wire, I think at after the close. Mention of MUSE. Sales Of Impotence Drugs Expected To Continue To Rise In 1998 Dow Jones Online News, Thursday, April 09, 1998 at 17:48 WASHINGTON -(Dow Jones)- Industry watchers expect sales of impotence drugs to continue to soar. According to IMS America, a company that follows pharmaceuticals, the "sexual disorder" market had sales of $156.7 million off 1.2 million prescriptions in 1997. Sales nearly quadrupled over 1996's $35.1 million. IMS said Thursday it expects big numbers for 1998 with last month's approval of Pfizer Inc.'s (PFE) drug Viagra, the first pill for the disorder. Other impotence drugs are injected. Vivus Inc. (VVUS) led last year with sales of $108.3 million for its two products Muse and Actis. Pharmacia & Upjohn Inc.'s (PNU) Caverject had $47 million in sales and Schwartz Pharma's Edex, which hit the market late last year, had $1.4 million in sales. -Otesa Middleton; 202-862-6654 Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.

To: VLAD who wrote (6764)	4/9/1998 8:11:00 PM
From: E'Lane	Read Replies (1) \| Respond to of 23519

ON TOPIC VLAD Agree on the need for getting this product out to the doc's offices. IMHO, I think they need to send it to the OBGYN's..after all, not many men are going to admit to a problem (too macho) and the women are all gonna cry to their docs cause they think it is "their fault". If these Drs. have the info, then the women will make sure the men are made aware of it. How many men watching the Superbowl were gonna admit to such a personal problem..big ole macho football fans don't want to see these commercials. Maybe during ER or something, but not during a ball game and not in front of the guys! Heartstream had their portable defribulator written into an ER episode. Free advertising. Don't know why the same couldn't be done with ED. Those writers are always looking for a new "problem" to address. Regards, E'Lane

To: VLAD who wrote (6764)	4/10/1998 3:03:00 AM
From: LoLoLoLita	Read Replies (2) \| Respond to of 23519

VLAD, it's not just the $14.75 price they paid, it's also the fact (which they knew in December), that they were facing large increases in spending for Q1 (with what turned out to be a $0.07/share operating deficit), and what seems now like the possibility (to me at least) of another deficit in Q2. why did they have to spend $26 M on buying back shares at all? could they have been stupid enough to think that they would trigger a short squeeze and drive up the price? if so, that's not responsible management. when i went over the balance sheet, it sure looked like there was a good possibility that they will have to take on debt in Q2 to pay for their increased spending. wouldn't shareholder value have been better served by using the $26 M as a cushion for their increased spending, rather than blowing it on buying stock at a price that i daresay few, if any, of even the most rabid bulls here were loading up the truck with VVUS? David